Monte Rosa Therapeutics, Inc. (GLUE)
Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 5, 2026
Profit #1338 of 1484 companies
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | |
|---|---|---|---|---|
| ROE/ROA | 7.5% | 8.7% | 8.7% | 10.6% |
Growth #1482 of 1484 companies
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | |
|---|---|---|---|---|
| Sales andOCF growth | -130.3% | -123.8% | -41.9% |
Payout #1117 of 1484 companies
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | |
|---|---|---|---|---|
| Shareholderdistributions/ net income | 0% | 0% | 0% |
Safety #777 of 1484 companies
| Balance | Stability | |
|---|---|---|
| Equity/assets andOCF stability | 71.9% | -54.6% |
Price #1434 of 1484 companies
| Earnings | FCF | |
|---|---|---|
| Earnings andFCF yield | $-15.57 | $-3.10 |
